Publications in collaboration with researchers from Hospital de Galdakao - Usansolo (14)

1994

  1. Cholylglycine serum levels in cirrhosis: A clinical and laboratory evaluation

    European Journal of Gastroenterology and Hepatology, Vol. 6, Núm. 2, pp. 175-178

1993

  1. A clinical and biochemical study on tissue polypeptide antigen (TPA) in non-malignant hepatic disorders

    Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 53, Núm. 6, pp. 633-637

  2. Serum CA 125 levels in patients with non-malignant liver diseases without ascites

    The Clinical Investigator, Vol. 71, Núm. 3, pp. 239

  3. Serum Levels of CA 50 in Nonmalignant Liver Diseases: A Clinical and Biochemical Study

    The American Journal of Gastroenterology, Vol. 88, Núm. 3, pp. 409-412

  4. Study of the tumor marker carbohydrate antigen 50 in liver cirrhosis: Pathogenetic considerations

    Clinical Nuclear Medicine, Vol. 18, Núm. 1, pp. 56-59

1992

  1. A clinical and laboratory evaluation of the behavior of tissue polypeptide antigen in liver cirrhosis

    Digestion, Vol. 53, Núm. 3-4, pp. 157-161

  2. Breast cancer-associated antigen ca 15.3 in liver cirrhosis

    Acta Oncologica, Vol. 31, Núm. 7, pp. 741-744

  3. CA 125 serum levels in patients with non-neoplastic liver diseases. A clinical and laboratory study

    Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 52, Núm. 3, pp. 201-206

  4. CA 19-9 in non-neoplastic liver diseases. A clinical and laboratory study

    Clinica Chimica Acta, Vol. 210, Núm. 1-2, pp. 145-151

  5. Evaluation of the behavior of carcinoembryonic antigen in cirrhotic patients

    International Journal of Biological Markers, Vol. 7, Núm. 4, pp. 244-248

  6. Preliminary study of alpha-fetoprotein in nonmalignant liver diseases. A clinico-biochemical evaluation

    International Journal of Biological Markers, Vol. 7, Núm. 2, pp. 97-102

  7. Tissue polypeptide antigen (TPA) in chronic active hepatitis and mild liver diseases

    International Journal of Biological Markers, Vol. 7, Núm. 4, pp. 249-252

1991

  1. CA 15.3 in nonmalignant liver diseases

    International Journal of Biological Markers, Vol. 6, Núm. 3, pp. 188-192

  2. Neuron-specific enolase concentrations in serum in benign liver diseases

    Clinical Chemistry, Vol. 37, Núm. 4, pp. 579-581